The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

Michelle V. Dietz, MD, Job P. van Kooten, MD, Jeroen L. A. van Vugt, MD, PhD, Alexandra R. M. Brandt-Kerkhof, MD, Cornelis Verhoef, MD, PhD, and Eva V. E. Madsen, MD, PhD

Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands

ABSTRACT

**Background.** Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a potentially curative treatment for peritoneal metastases from colorectal cancer (CRC) or pseudomyxoma peritonei (PMP). Because of the considerable morbidity of this treatment, optimal patient selection is key. This study aimed to assess the impact of low skeletal muscle mass (SMM) on outcomes after CRS-HIPEC.

**Methods.** Patients who underwent CRS-HIPEC between 2014 and 2020 at a tertiary center were included. SMM was measured on computed tomography by means of the L3 muscle index. Postoperative complications and survival outcomes were compared between groups by use of logistic regression and Kaplan-Meier survival analyses.

**Results.** Of 284 included patients, 149 had low SMM. Occurrence of severe postoperative complications did not differ between groups (28.9% for patients with low vs. 34.1% for patients with normal SMM). Low SMM was not associated with postoperative complications ($p = 0.344$).

For CRC patients, no significant differences were observed in disease-free (DFS) or overall survival (OS) between patients with low (median DFS 7 months [IQR 4–14], median OS 33 months [IQR 14–NR]) and patients with normal SMM (median DFS 8 months [IQR 5–20], median OS 35 months [IQR 18–NR]). Regarding PMP, survival outcomes did not significantly differ between groups (3-year DFS 47.3% for patients with low SMM vs. 54.5% for patients with normal SMM, $p = 0.676$; 3-year OS 70.8% vs. 90.9% respectively, $p = 0.172$).

**Conclusions.** Low SMM could not be identified as a predictor of severe complications or survival outcomes after CRS-HIPEC.

Cytoreductive surgery (CRS) combined with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is considered to be a potentially curative treatment for selected patients with peritoneal metastases (PM) from colorectal carcinoma (CRC) or pseudomyxoma peritonei (PMP). This extensive surgical treatment significantly improves the survival of CRC patients compared with systemic chemotherapy, resulting in 5-year survival rates of up to 40%.1–5 For PMP patients CRS-HIPEC is considered the golden standard with 5-year survival rates of 74%.6 Despite these improvements in survival, CRS-HIPEC is associated with considerable postoperative morbidity. Severe postoperative complications are reported in approximately 30% of the patients.4, 7, 8 Previous studies have shown an association between the occurrence of postoperative complications and impaired survival outcomes.6, 9, 10 Hence, for this select patient population, it is of great importance to identify risk factors for postoperative outcomes that could aid in preoperative patient selection.

With the increasing emphasis on prehabilitation in cancer surgery, potential risk factors associated with the nutritional status are widely investigated. As the number of obese cancer patients is rising, the utility of factors like...
BMI and weight loss is under debate. A potential risk factor of interest is sarcopenia, which is mainly determined by the loss of skeletal muscle mass (SMM) and can easily remain unnoticed in obese patients. Several studies showed that SMM was an independent predictor of outcomes after colorectal cancer surgery, and was better in predicting outcomes than other factors representing the patients’ nutritional status, like BMI or albumin. A few studies report on the impact of SMM in patients undergoing CRS-HIPEC for PM from CRC or PMP, and conflicting results have been published.

The aim of this retrospective study was to identify the impact of low SMM on postoperative outcomes after CRS-HIPEC for these patients. The hypothesis was that low SMM can be a valid predictor of severe postoperative complications and impaired survival outcomes. Hence, preoperative SMM measurement can potentially aid in preoperative patient selection.

METHODS

Study Population

All patients who underwent CRS-HIPEC for PM from CRC or PMP at the Erasmus MC Cancer Institute in Rotterdam, the Netherlands, between March 2014 and June 2020 were included in this study. Erasmus MC is a university hospital and tertiary referral center for patients with extensive (metastasized) colorectal cancer. Patients were excluded if a suitable preoperative computed tomography (CT) image or patient body height, both essential for SMM measurement, were not available. Relevant patient and disease-related characteristics, operation details, and postoperative outcomes were extracted from a prospectively maintained database. This study was approved by the local Medical Ethics Review Committee of Erasmus MC (MEC-2018-1286).

Surgical Procedure

CRS-HIPEC procedures were performed by a specialized surgical team, in accordance with the Dutch CRS and HIPEC protocol. After abdominal access via laparotomy, the peritoneal cancer index (PCI) according to Jacquet and Sugarbaker was used to estimate the tumor load. For patients with PM from CRC, cytoreductive surgery was performed if the PCI score was under 20 and/or the specialized surgeons presumed the PM to be resectable. For patients with PM from PMP, the PCI score was not considered for determining CRS-HIPEC feasibility.

Postoperative Monitoring

Patients were postoperatively treated following standard local protocol for CRS-HIPEC. Postoperative complications were categorized according to the Clavien-Dindo classification. Severe postoperative complications were defined as Clavien-Dindo grade 3 or higher (i.e., re-intervention, extended ICU stay/readmission to ICU, or treatment-related death). In case of multiple complications, the highest-grade complication was registered. The postoperative period was defined as 30 days after CRS-HIPEC, or the duration of the entire hospital stay, when exceeding 30 days.

Follow-Up

Follow-up was performed at the outpatient clinic by use of CT imaging and monitoring of the carcino-embryonal antigen (CEA). CEA was determined every 3 months and a CT examination was performed every 6 months during the first 2 postoperative years. After 2 years, the follow-up interval for CEA was 6 months and a CT scan was made every 12 months. A CT scan was also performed in case of increasing CEA levels or complaints, suspicious for recurrent disease. Follow-up was completed after a disease-free interval of 5 years following CRS-HIPEC.

Skeletal Muscle Mass (SMM) Measurement

Abdominal CT was routinely performed during preoperative assessment. For patients treated with neo-adjuvant chemotherapy, SMM measurements were performed on the CT scan that was made after neo-adjuvant treatment. SMM was determined by using FatSeg software (developed by the Biomedical Imaging Group Rotterdam of Erasmus MC, Rotterdam, the Netherlands, based on MeVisLab [Mevis Medical Solutions, Bremen, Germany]). In summary, SMM was measured twice at the level of the third lumbar vertebra (L3) on two different slices showing both transversal processes. The psoas, paraspinal, transverse abdominal, external oblique, internal oblique, and rectus abdominis muscles were manually traced (Fig. 1). The SMM area was computed automatically using the preset Hounsfield unit (HU) intensity thresholds (between –30 and –150), and was expressed in square centimeters. The L3 muscle index was calculated by dividing the average of the two L3 muscle area measurements by the squared patient height (cm²/m²). Low SMM was defined using the cut-off values of 43 cm²/m² for men with BMI < 25 cm²/m², 53 cm²/m² for men with BMI ≥ 25 and 41 cm²/m² for women, independent of BMI. These were developed in an oncological population to predict survival. The SMM measurements were performed by a member of the
research group (MD). A second investigator (JK) performed a random control on 10% of the examinations.

Primary and Secondary Outcomes

The primary outcome of this study was defined as the occurrence of severe postoperative complications (i.e., Clavien-Dindo grade 3 or higher). Secondary outcomes were disease-free survival (DFS) and overall survival (OS). DFS was defined as the time interval in months between CRS-HIPEC and date of recurrence or death. OS was defined as the time interval in months between CRS-HIPEC and date of death. Information on survival status was obtained from the national civil registry. When no event occurred, patients were censored at the date of the last follow-up visit for DFS or the date of last request of survival status for OS.

Statistical Analysis

Continuous variables were expressed as median with interquartile range (IQR). Categorical variables were presented as counts with percentages. Continuous variables were compared between patients with low and normal SMM using the Mann-Whitney $U$ test. Categorical variables were compared using the chi-square test or Fisher’s exact test if less than 5 events occurred. An intra-class correlation coefficient (ICC) based on a mean-rating ($k = 3$), absolute-agreement, 2-way mixed-effects model, was estimated to investigate the reliability of the SMM measurements of the two investigators. To determine the effect of low SMM on the occurrence of severe postoperative complications, corrected for other possible risk factors, multivariable linear regression with backward selection was used. Gender, age, BMI, ASA (American Society of Anesthesiologists) classification, and primary tumor type were entered in the multivariable model. Smoking history, PCI, presence of anastomosis and intraoperative blood loss are known predictive variables and were also entered in the model.26–28 The log-rank was used to compare OS and DFS between patients with low and normal SMM. Survival analysis was performed separately for CRC and PMP patients because of different prognoses. All tests were two-sided and differences were considered statistically significant when $p < 0.05$. All statistical analyses were performed using Statistical Package for Social Sciences (SPSS) version 25.0 (IBM Corporation, Armonk, NY, USA). Kaplan-Meier survival curves were created using R version 4.0.2 (https://www.r-project.org/).

RESULTS

During the study period, 244 patients (83.6%) underwent CRS-HIPEC for PM from CRC and 48 patients (16.4%) from PMP. Five CRC patients and three PMP patients were excluded from analyses because of the absence of a suitable preoperative CT for SMM measurement. The degree of reliability between the SMM measurements of the two investigators was high. The single measure ICC was 0.924 (95% CI 0.824–0.964, $p < 0.001$).

Baseline and Intraoperative Characteristics

A total of 149 patients (52.5%) had low SMM. Baseline and intraoperative characteristics are displayed in Tables 1 and 2, respectively. Patients with low SMM were significantly more often woman than patients with normal SMM (55.0% vs. 42.2%, $p = 0.031$). Body mass index (BMI) was significantly lower for patients with low SMM (median 25.0 vs. 27.5, $p < 0.001$). Other baseline characteristics and intraoperative characteristics did not significantly differ between the groups. The median interval from preoperative
## TABLE 1  Baseline Characteristics

|                        | Total N = 284 (100) | Low SMM N = 149 (52.5) | Normal SMM N = 135 (47.5) | p-value |
|------------------------|---------------------|------------------------|---------------------------|---------|
| **Gender**             |                     |                        |                           |         |
| Male                   | 145 (51.1)          | 67 (45.0)              | 78 (57.8)                 | 0.031*  |
| Female                 | 139 (48.9)          | 82 (55.0)              | 57 (42.2)                 |         |
| **Age (years)**        | 62 [53–70]          | 63 [53–70]             | 61 [53–69]                | 0.593   |
| **BMI (kg/m²)**        | 25.9 [23.1–29.2]    | 25.0 [22.0–27.4]       | 27.5 [24.3–30.5]          | < 0.001*|
| Smoking (past or current) |                   |                        |                           |         |
| Yes                    | 126 (46.2)          | 69 (49.6)              | 57 (42.5)                 | 0.239   |
| No                     | 147 (53.8)          | 70 (50.4)              | 77 (57.5)                 |         |
| Missing                | 11 (3.9)            | 10 (6.7)               | 1 (0.7)                   |         |
| **Diabetes**           |                     |                        |                           |         |
| Yes                    | 31 (11.0)           | 19 (12.8)              | 12 (8.9)                  | 0.288   |
| No                     | 252 (89.0)          | 129 (87.2)             | 123 (91.1)                |         |
| Missing                | 1 (0.4)             | 1 (0.7)                | 0 (0)                     |         |
| **Hypertension**       |                     |                        |                           |         |
| Yes                    | 77 (27.4)           | 37 (25.2)              | 40 (29.9)                 | 0.380   |
| No                     | 204 (72.6)          | 110 (74.8)             | 94 (70.1)                 |         |
| Missing                | 3 (1.1)             | 2 (1.3)                | 1 (0.7)                   |         |
| **ASA-classification** |                     |                        |                           |         |
| 1                      | 45 (16.1)           | 23 (15.8)              | 22 (16.5)                 | 0.975   |
| 2                      | 174 (62.4)          | 91 (62.3)              | 83 (62.4)                 |         |
| ≥ 3                    | 60 (21.5)           | 32 (21.9)              | 28 (21.1)                 |         |
| Missing                | 5 (1.8)             | 3 (2.0)                | 2 (1.5)                   |         |
| **Primary tumor**      |                     |                        |                           |         |
| PMP                    | 45 (15.8)           | 24 (16.1)              | 21 (15.6)                 | 0.467   |
| Appendix               | 16 (5.6)            | 6 (4.0)                | 10 (7.4)                  |         |
| CRC                    | 223 (78.5)          | 119 (79.9)             | 104 (77.0)                |         |
| **Primary location CRC** |                   |                        |                           |         |
| Ascending colon        | 82 (36.8)           | 48 (40.3)              | 34 (32.7)                 | 0.613   |
| Transverse colon       | 19 (8.5)            | 9 (7.6)                | 10 (9.6)                  |         |
| Descending colon       | 23 (10.3)           | 14 (11.8)              | 9 (8.7)                   |         |
| Sigmoid                | 69 (30.9)           | 34 (28.6)              | 35 (33.7)                 |         |
| Rectum                 | 30 (13.5)           | 14 (11.8)              | 16 (15.4)                 |         |
| **T stage primary tumor** |                 |                        |                           |         |
| T1                     | 6 (2.6)             | 2 (1.6)                | 4 (3.6)                   | 0.651   |
| T2                     | 10 (4.3)            | 4 (3.3)                | 6 (5.4)                   |         |
| T3                     | 105 (44.9)          | 57 (46.7)              | 48 (42.9)                 |         |
| T4                     | 113 (48.3)          | 59 (48.4)              | 54 (48.2)                 |         |
| Missing                | 5 (2.1)             | 3 (2.4)                | 2 (1.8)                   |         |
| **N stage primary tumor** |                |                        |                           |         |
| N0                     | 64 (28.4)           | 39 (32.8)              | 25 (23.6)                 | 0.311   |
| N1                     | 88 (39.1)           | 44 (37.0)              | 44 (41.5)                 |         |
| N2                     | 73 (32.4)           | 36 (30.3)              | 37 (34.9)                 |         |
| Missing                | 14 (5.9)            | 6 (4.8)                | 8 (7.0)                   |         |
| **M stage primary tumor** |                |                        |                           |         |
| M0                     | 100 (48.5)          | 51 (46.4)              | 49 (51.0)                 | 0.503   |
| M1                     | 106 (51.5)          | 59 (53.6)              | 47 (49.0)                 |         |
| Missing                | 33 (13.8)           | 15 (12.0)              | 18 (15.8)                 |         |
CT to surgery was 5 weeks for both patients with low (IQR 3–8) and normal SMM (IQR 2–8).

Postoperative Outcomes

There were no differences in the occurrence of severe postoperative complications in general (i.e., Clavien-Dindo 3 or higher) between the groups (Table 3). Patients with normal SMM had a perforation significantly more often (i.e., bowel perforation $n = 6$, gallbladder perforation $n = 1$) than patients with low SMM (bowel perforation $n = 1$, $p = 0.022$). Other postoperative outcomes did not significantly differ between the groups. Low SMM was not associated with severe postoperative complications in univariate logistic regression analysis (OR 0.79, 95% CI 0.48–1.30, $p = 0.344$; Table 4). Significant risk factors in univariate analysis were male gender (OR 2.67, 95% CI 1.58–4.53, $p < 0.001$), smoking (OR 1.76, 95% CI 1.06–2.94, $p = 0.030$) and more intraoperative blood loss (OR 1.34, 95% CI 1.04–1.73, $p = 0.021$). In a multivariable analysis, male

| Liver metastases$^{a,b}$ | Total $N = 284$ (100) | Low SMM $N = 149$ (52.5) | Normal SMM $N = 135$ (47.5) | $p$-value |
|--------------------------|-----------------------|--------------------------|----------------------------|-----------|
| Yes                      | 23 (9.6)              | 16 (12.8)                | 7 (6.1)                    | 0.081     |

| Differentiation$^a$ | Total $N = 284$ (100) | Low SMM $N = 149$ (52.5) | Normal SMM $N = 135$ (47.5) | $p$-value |
|---------------------|-----------------------|--------------------------|----------------------------|-----------|
| Good                | 31 (16.0)             | 18 (17.0)                | 13 (14.8)                  | 0.930     |
| Moderate            | 129 (66.5)            | 71 (67.0)                | 58 (65.9)                  |           |
| Poor                | 18 (9.3)              | 9 (8.5)                  | 9 (10.2)                   |           |
| Signet              | 16 (8.2)              | 8 (7.5)                  | 8 (9.1)                    |           |
| Missing             | 45 (18.8)             | 19 (15.2)                | 26 (22.8)                  |           |

| Mucinous$^a$ | Total $N = 284$ (100) | Low SMM $N = 149$ (52.5) | Normal SMM $N = 135$ (47.5) | $p$-value |
|--------------|-----------------------|--------------------------|----------------------------|-----------|
| Yes          | 50 (23.1)             | 21 (18.3)                | 29 (28.7)                  | 0.069     |
| No           | 166 (76.9)            | 94 (81.7)                | 72 (71.3)                  |           |
| Missing      | 23 (9.6)              | 10 (8.0)                 | 13 (11.4)                  |           |

| Histopathology PMP$^c$ | Total $N = 284$ (100) | Low SMM $N = 149$ (52.5) | Normal SMM $N = 135$ (47.5) | $p$-value |
|------------------------|-----------------------|--------------------------|----------------------------|-----------|
| DPAM                   | 39 (86.7)             | 21 (87.5)                | 18 (85.7)                  | 0.860     |
| PMCA                   | 13 (13.3)             | 3 (12.5)                 | 3 (14.3)                   |           |
| PMCA-I                 | 0 (0)                 | 0 (0)                    | 0 (0)                      |           |

| PM onset$^a$ | Total $N = 284$ (100) | Low SMM $N = 149$ (52.5) | Normal SMM $N = 135$ (47.5) | $p$-value |
|--------------|-----------------------|--------------------------|----------------------------|-----------|
| Synchronous  | 113(47.3)             | 65 (52.0)                | 48 (42.1)                  | 0.126     |
| Metachronous | 126 (52.7)            | 60 (48.0)                | 66 (57.9)                  |           |

| PSS | Total $N = 284$ (100) | Low SMM $N = 149$ (52.5) | Normal SMM $N = 135$ (47.5) | $p$-value |
|-----|-----------------------|--------------------------|----------------------------|-----------|
| 0   | 25 (8.8)              | 12 (8.1)                 | 13 (9.6)                   | 0.925     |
| 1   | 47 (16.5)             | 25 (16.8)                | 22 (16.3)                  |           |
| 2   | 201 (70.8)            | 107 (71.8)               | 94 (69.6)                  |           |
| 3   | 11 (3.9)              | 5 (3.4)                  | 6 (4.4)                    |           |

| Neo-adjuvant chemotherapy$^d$ | Total $N = 284$ (100) | Low SMM $N = 149$ (52.5) | Normal SMM $N = 135$ (47.5) | $p$-value |
|-------------------------------|-----------------------|--------------------------|----------------------------|-----------|
| Yes                           | 33 (11.6)             | 22 (14.8)                | 11 (8.1)                   | 0.082     |
| CT-to-surgery interval (weeks) | 5 [2–8]               | 5 [3–8]                  | 5 [2–8]                    | 0.326     |

Continuous variables are shown as median [IQR]. Frequencies are shown as N (%), excluding ‘missing’

BMI body mass index, ASA American Association for Anesthesiology, PMP pseudomyxoma peritonei, CRC colorectal carcinoma, PM peritoneal metastasis, DPAM disseminated peritoneal adenomucinosis, PMCA peritoneal mucinous carcinomatosis, PMCA-I peritoneal mucinous carcinomatosis with intermediate features, PSS prior surgical score

$^a$Proportion of CRC patients ($n = 239$)

$^b$Synchronous liver metastasis to primary colorectal tumor

$^c$Proportion of PMP patients ($n = 45$)

$^d$Neo-adjuvant chemotherapy to CRS-HIPEC

$^e_{2} < 0.05$
gender (OR 2.67, 95% CI 1.58–4.53, p < 0.001), smoking (OR 1.76, 95% CI 1.06–2.94, p = 0.030), and more intraoperative blood loss (OR 1.34, 95% CI 1.04–1.73, p = 0.021) remained significantly associated with the occurrence of severe postoperative complications.

### Survival Outcomes

Median follow-up time for surviving CRC patients was 24 months (IQR 12–37). A total of 179 CRC patients (73.4%) had recurrence of disease during follow-up and the median DFS was 8 months (IQR 4–16). There was no significant difference in median DFS between patients with low and patients with normal SMM (7 [IQR 4–14] vs. 8 months [IQR 5–20], p = 0.078; Fig. 2A). Median OS for CRC patients was 33 months (IQR 17–NR [not reached]). The median OS (33 months, IQR 14–NR) for CRC patients with low SMM did not significantly differ from CRC patients with normal SMM (35 months, IQR 18–NR, p = 0.195, Fig. 2B).

Median follow-up time for surviving PMP patients was 18 months (IQR 9–50). A total of 13 PMP patients (27.1%) had recurrence of disease during follow-up. For PMP patients the median DFS and OS were not yet reached. The 1- and 3-year DFS rates were 84.2% and 51.8%, respectively, for all PMP patients. For patients with low SMM,

| TABLE 2 Intraoperative characteristics | Total N = 284 (100) | Low SMM N = 149 (52.5) | Normal SMM N = 135 (47.5) | p-value |
|----------------------------------------|-------------------|----------------------|----------------------|---------|
| PCI                                    | 11 [6–16]         | 10 [6–16]            | 12 [7–17]            | 0.156   |
| CCR-score                              |                   |                      |                      |         |
| R1                                     | 277 (97.5)        | 147 (98.7)           | 130 (96.3)           | 0.340   |
| R2a                                    | 5 (1.8)           | 1 (0.7)              | 4 (3.0)              |         |
| R2b                                    | 2 (0.7)           | 1 (0.7)              | 1 (0.7)              |         |
| Procedure time (min)                   | 373 [304–438]     | 380 [306–435]        | 365 [303–451]        | 0.880   |
| Blood loss (l)                         | 1.0 [0.6–1.6]     | 0.9 [0.6–1.5]        | 1.0 [0.6–1.8]        | 0.265   |
| HIPEC regimen                          |                   |                      |                      |         |
| MMC                                    | 261 (91.9)        | 140 (94.0)           | 121 (89.6)           | 0.182   |
| Oxaliplatin                            | 23 (8.1)          | 9 (6.0)              | 14 (10.4)            |         |
| Resections                             |                   |                      |                      |         |
| Omentum                                | 267 (94.0)        | 142 (95.3)           | 125 (92.6)           | 0.336   |
| Peritoneum                             | 214 (75.4)        | 116 (77.9)           | 98 (72.6)            | 0.304   |
| Diaphragm                              | 60 (21.1)         | 28 (18.8)            | 32 (23.7)            | 0.311   |
| Stomach                                | 4 (1.4)           | 3 (2.0)              | 1 (0.7)              | 0.363   |
| Small bowel                            | 75 (26.4)         | 41 (27.5)            | 34 (25.2)            | 0.656   |
| Colon                                  | 169 (59.5)        | 82 (55.0)            | 87 (64.4)            | 0.107   |
| Rectum                                 | 60 (21.1)         | 31 (20.8)            | 29 (21.5)            | 0.889   |
| Gallbladder                            | 18 (6.3)          | 10 (7.4)             | 8 (5.4)              | 0.481   |
| Pancreas                               | 12 (4.2)          | 6 (4.4)              | 6 (4.0)              | 0.861   |
| Spleen                                 | 22 (7.7)          | 8 (5.9)              | 14 (9.4)             | 0.275   |
| Pelvic organsa                         | 160 (56.3)        | 89 (59.7)            | 71 (52.6)            | 0.226   |
| Synchronous liver treatment b          | 33 (11.6)         | 22 (14.8)            | 11 (8.1)             | 0.082   |
| Anastomosis                            |                   |                      |                      |         |
| Yes                                    | 163 (57.4)        | 81 (54.4)            | 82 (60.7)            | 0.278   |
| Median number/patient                  | 1 [0–1]           | 1 [0–1]              | 1 [0–1]              | 0.723   |
| Stoma                                  |                   |                      |                      |         |
| Ileostomy                              | 15 (5.3)          | 7 (4.7)              | 8 (5.9)              | 0.106   |
| Colostomy                              | 85 (29.9)         | 37 (24.8)            | 48 (35.6)            |         |

Continuous variables are shown as median [IQR]. Frequencies are shown as N (%), excluding ‘missing’

PCI Peritoneal Cancer Index, CCR completeness of cytoreduction, MMC mitomycin-C

aPelvic organs including urinary bladder, ovaries, uterus, ureters and pelvis

bLiver treatment during CRS-HIPEC procedure: hepatic resection (n = 24) or radiofrequency ablation (RFA, n = 9)
the 1- and 3-year DFS rates were 81.3\% and 47.3\%, respectively, compared with 87.8\% and 54.5\% for patients with normal SMM \((p = 0.676, \text{Fig. 2C)}\). The 1- and 3-year OS rates were 97.7\% and 80.4\%, respectively, for all PMP patients. The 1- and 3-year OS rates were 95.8\% and 70.8\%, respectively, for patients with low versus 100\% and 90.9\% for patients with normal SMM \((p = 0.172, \text{Fig. 2D)}\).

### Additional Analysis of Patients Who Did Not Receive Neo-adjuvant Chemotherapy to CRS-HIPEC

There was no significant difference in the occurrence of severe postoperative complications in general between groups for patients that did not receive neo-adjuvant chemotherapy to CRS-HIPEC (32.2\% for patients with normal SMM vs. 29.9\% for patients with low SMM, \(p = 0.689\)). In a multivariable analysis, male gender (OR 2.75, 95\% CI 1.49–5.06, \(p = 0.001\)), smoking (OR 2.19, 95\% CI 1.23–4.13, \(p = 0.008\)), and more intraoperative blood loss (OR 1.45, 95\% CI 1.08–1.93, \(p = 0.013\)) were significantly

| TABLE 3 Postoperative outcomes | Total \(N = 284\) (100) | Low SMM \(N = 149\) (52.5) | Normal SMM \(N = 135\) (47.5) | \(p\)-value |
|-------------------------------|-------------------------|--------------------------|--------------------------|-------------|
| Length of stay (days)         | 16 [12–20]              | 16 [12–19]               | 16 [12–22]               | 0.594       |
| Complications (any grade)     |                         |                          |                          |             |
| Any complication              | 181 (63.7)              | 98 (65.8)                | 83 (61.5)                | 0.453       |
| Anastomotic leakage\(^a\)    | 26 (9.2)                | 13 (8.7)                 | 13 (9.6)                 | 0.792       |
| Perforation\(^b\)            | 8 (2.8)                 | 1 (0.7)                  | 7 (5.2)                  | 0.022\(*\)  |
| Postoperative hemorrhage      | 11 (3.9)                | 8 (5.4)                  | 3 (2.2)                  | 0.170       |
| Intra-abdominal abscess       | 33 (11.6)               | 16 (10.7)                | 17 (12.6)                | 0.626       |
| Ileus/gastroparesis\(^c\)    | 48 (16.9)               | 28 (18.8)                | 20 (14.8)                | 0.372       |
| Wound infection               | 20 (7.0)                | 7 (4.7)                  | 13 (9.6)                 | 0.105       |
| Wound dehiscence              | 8 (2.8)                 | 2 (1.3)                  | 6 (4.4)                  | 0.115       |
| Chylous leakage               | 10 (3.5)                | 5 (3.4)                  | 5 (3.7)                  | 0.874       |
| Pneumonia                     | 15 (5.3)                | 10 (6.7)                 | 5 (3.7)                  | 0.258       |
| Pulmonary embolism            | 9 (3.2)                 | 3 (2.0)                  | 6 (4.4)                  | 0.243       |
| Cardiac complications         | 13 (4.6)                | 5 (3.4)                  | 8 (5.9)                  | 0.301       |
| UTI                           | 20 (7.0)                | 13 (8.7)                 | 7 (5.2)                  | 0.244       |
| Severe complication\(^d\)    | 89 (31.3)               | 43 (28.9)                | 46 (34.1)                | 0.344       |
| Reoperations                  | 43 (15.1)               | 20 (13.4)                | 23 (17.0)                | 0.396       |
| Clavien-Dindo grade           |                         |                          |                          |             |
| I                             | 19 (6.7)                | 11 (7.4)                 | 8 (5.9)                  | 0.946       |
| II                            | 73 (25.7)               | 42 (28.2)                | 31 (23.0)                |             |
| IIIa                          | 39 (13.7)               | 19 (12.8)                | 20 (14.8)                |             |
| IIIb                          | 32 (11.3)               | 16 (10.7)                | 16 (11.9)                |             |
| IVa                           | 10 (3.5)                | 5 (3.4)                  | 5 (3.7)                  |             |
| IVb                           | 2 (0.7)                 | 1 (0.7)                  | 1 (0.7)                  |             |
| V                             | 6 (2.1)                 | 2 (1.3)                  | 4 (3.0)                  |             |
| Adjuvant chemotherapy         |                         |                          |                          |             |
| Yes                           | 38 (13.4)               | 20 (13.4)                | 18 (13.3)                | 0.982       |

Continuous variables are shown as median [IQR]. Frequencies are shown as \(N\) (%), excluding ‘missing’

\(\text{UTI}\) urinary tract infection

\(^a\)Proportion of patients with a bowel anastomosis after CRS-HIPEC \((n = 163)\)

\(^b\)Perforation: bowel perforation \((n = 7)\), gallbladder perforation \((n = 1)\)

\(^c\)Ileus \((n = 11)\), gastroparesis \((n = 42)\)

\(^d\)Clavien-Dindo classification \(\geq \text{III}\) (i.e., re-intervention, extended ICU stay/readmission to ICU, or treatment-related death)

\(^*\)\(p < 0.05\)
associated with the occurrence of severe postoperative complications. For CRC patients that did not receive neo-adjuvant chemotherapy to CRS-HIPEC, median DFS was significantly shorter for patients with low SMM (7 [IQR 4–13] vs. 8 months [IQR 5–20], \( p = 0.019 \); Supplementary Fig. 1A). Median OS was 35 months for the normal SMM group [IQR 19–NR] versus 33 months in the low SMM group [IQR 15–56] (\( p = 0.124 \), Supplementary Fig. 1B).

None of the PMP patients received neo-adjuvant chemotherapy to CRS-HIPEC.

**DISCUSSION**

The aim of this study was to identify the impact of low skeletal muscle mass (SMM) on postoperative outcomes in patients undergoing CRS-HIPEC for peritoneal metastases (PM) from colorectal carcinoma (CRC) or pseudomyxoma peritonei (PMP). The current study found no association between low SMM and the occurrence of severe postoperative complications or survival outcomes.

Previous studies, reporting on the impact of sarcopenia in general colorectal cancer surgery, showed that low SMM was associated with higher rates of postoperative complications and impaired survival.\(^{12, 16, 29, 30}\) Therefore, low SMM has been proposed to aid in preoperative patient selection. This could be especially helpful for patients suffering from PM from CRC, because of their limited prognosis and considerable postoperative morbidity after CRS-HIPEC. CT scans are routinely performed as part of the preoperative assessment for CRS-HIPEC. Measurement of SMM on these CT scans could be used in preoperative patient selection. However, the current study could not reproduce an association between low SMM and postoperative outcomes in patients undergoing CRS-HIPEC. This is in line with other studies that investigated the impact of SMM in this specific patient population.\(^{18–20}\) An explanation for the discrepancy between general colorectal surgery and CRS-HIPEC might be the strict preoperative patient selection for CRS-HIPEC, mainly based on fitness for major surgery, leading to (strong) selection bias. Indeed, the vast majority of patients (around 80%) had an ASA classification of 1 or 2. The impact of low SMM on postoperative outcomes might be smaller in this strictly selected population, in contrast to the less selected patient population undergoing general colorectal cancer surgery.

One study regarding postoperative complications in patients undergoing CRS-HIPEC for PM from CRC, by Van Vugt et al., reported that patients with skeletal muscle depletion had significantly more reoperations than patients with normal SMM. They also found that lower SMM as a continuous measure, was independently associated with a

| TABLE 4 Logistic regression for predictors of severe postoperative complications (i.e., Clavien-Dindo ≥ 3) |
|-----------------------------------------------|
| **Univariable OR (95% CI)** | **p-value** | **Multivariable OR (95% CI)** | **p-value** |
| Low SMM | 0.79 (0.48–1.30) | 0.344 |  |  |
| Gender |  |  |  |  |
| Female | 1 |  | 1 |  |
| Male | 2.67 (1.58–4.53) | <0.001* | 2.54 (1.44–4.48) | 0.001* |
| Age (years) | 1.02 (0.99–1.04) | 0.199 |  |  |
| BMI (kg/m\(^2\)) | 1.01 (0.96–1.07) | 0.648 |  |  |
| Smoking (past or current) | 1.76 (1.06–2.94) | 0.030* | 2.19 (1.24–3.84) | 0.007* |
| ASA-classification |  |  |  |  |
| 1 | 1 |  |  |  |
| 2 | 1.14 (0.55–2.34) | 0.725 |  |  |
| ≥ 3 | 1.23 (0.53–2.85) | 0.628 |  |  |
| Primary tumor |  |  |  |  |
| CRC | 1 |  |  |  |
| Appendix | 1.43 (0.50–4.09) | 0.508 |  |  |
| PMP | 1.44 (0.74–2.82) | 0.281 |  |  |
| PCI | 1.03 (0.99–1.06) | 0.061 |  |  |
| Blood loss (l) | 1.34 (1.04–1.73) | 0.021* | 1.46 (1.11–1.94) | 0.008* |
| Anastomosis | 1.40 (0.83–2.33) | 0.204 |  |  |

BMI body mass index, ASA American Association of Anesthesiology, PMP pseudomyxoma peritonei, CRC colorectal carcinoma, PCI peritoneal cancer index

\*\*a < 0.05

\*Appendiceal adenocarcinoma
higher rate of severe postoperative complications.\textsuperscript{17} However, they did not find this association when using SMM as a dichotomous variable (i.e., low vs. normal SMM). To increase the potential for clinical use, the current authors decided to use the SMM as a dichotomous variable. However, there is no consensus in the field as to which cut-off values should be used to define low SMM. Previous studies, including the study by Van Vugt et al., used cut-off values defined by Prado et al.\textsuperscript{31} These values have been acknowledged in an international consensus statement on cancer cachexia and have been validated for mortality prediction in obese patients with pulmonary and gastrointestinal cancer.\textsuperscript{32} It is questionable whether these values are applicable in the current, mostly non-obese, cohort. Martin et al. more recently proposed cut-off values based on a general patient population with pulmonary and gastrointestinal malignancies, which were stratified for sex and BMI.\textsuperscript{11} These cut-offs were applied because they were considered more appropriate for the current study. Nevertheless, we could not demonstrate a relation between low SMM and severe postoperative complications or reoperations after CRS-HIPEC. Van Vugt et al. included patients that underwent CRS-HIPEC between 2005 and 2013, whereas the current cohort consists of patients that underwent CRS-HIPEC from 2014. Preoperative patient selection regarding CRS-HIPEC has most likely improved during the last decade, resulting in stricter patient selection.

Another explanation could be that patients with low SMM were significantly more often women. This is in line with the study of Martin et al., in which these cut-off values were proposed.\textsuperscript{11} In the current cohort, male gender was independently associated with severe postoperative complications.\textsuperscript{3} However, in multivariate analysis including sex, low SMM remained unassociated with severe postoperative complications. Besides one previous study that reported on a proportion of the current study population, the association between sex and postoperative complications has not been previously described for CRS-HIPEC.\textsuperscript{35} Previous studies on colorectal surgery reported an association between male sex and increased risk of anastomotic leakage.\textsuperscript{34, 35} One of these studies reported that the leak rate was especially high in men with low cancers.\textsuperscript{35} This study proposed that this might be explained by anatomical differences in the narrower male pelvis and hormonal differences that might influence the intestinal microcirculation. In the current cohort, other factors that were associated with severe

\textbf{FIG. 2} Kaplan-Meier survival curves for disease-free survival and overall survival for CRC (\textbf{a, b}) and PMP (\textbf{c, d}) patients with low versus normal SMM. The numbers at risk are displayed in the tables below each graph. The log-rank $p$-values are displayed in the bottom right corner of each graph.
postoperative complications were smoking and intraoperative blood loss. This conforms with previous studies on complications after CRS-HIPEC. 26, 27

The cut-off values that were proposed by Martin et al. to classify SMM as low or normal, were based on SMM measurements on CT scans that were made before receiving any treatment for the measurement of SMM. 11 In the current study, SMM measurements were performed on the most recent CT scan that was made for CRS-HIPEC. For patients that were treated with neo-adjuvant chemotherapy for CRS-HIPEC, this was the CT scan that was made after neo-adjuvant treatment. Previous studies have shown that neo-adjuvant therapy was associated with the loss of SMM. 36–38 The post-therapy CT scan provides a more reliable view of the patients’ physical status at time of surgery. However, concerning the utility of SMM measurements in patient selection for CRS-HIPEC, the possible effect of neo-adjuvant chemotherapy on SMM should be taken into account. In the current cohort, only a minority of patients (12%) received neo-adjuvant chemotherapy, and there was no significant difference between groups. An additional analysis, excluding the patients that were treated with neo-adjuvant chemotherapy to CRS-HIPEC, showed similar outcomes regarding the occurrence of severe postoperative complications and OS. CRC patients with low SMM who did not receive neo-adjuvant chemotherapy had a significantly shorter DFS (7 months) than patients with normal SMM (8 months). Although not statistically significant, slightly more patients in the low SMM group received neo-adjuvant chemotherapy (14.8%) than in the normal SMM group (8.1%). This supports the hypothesis that neo-adjuvant chemotherapy is associated with the loss of SMM. Besides the significant difference in DFS in this subgroup analysis, there is a trend towards a slightly better DFS and OS for patients with normal SMM in the general study population. Low SMM might affect survival outcomes, but larger numbers of patients may be needed to support this hypothesis due to the highly selected population of patients undergoing CRS-HIPEC.

Regarding PMP, a study by Galan et al. showed that OS was significantly higher in patients with normal SMM. 20 This difference was found in the first months after CRS-HIPEC, without a significant difference in the occurrence of severe postoperative complications. Galan et al. stated that patients with low SMM might have a higher risk of death when major complications occur. In the current cohort, the postoperative mortality for PMP patients was very low (i.e., n = 1), which explains why this difference in OS was not found.

The current study had some limitations. Due to the retrospective nature of the current study, additional data on muscle function or nutritional status could not be obtained. The European Working Group on Sarcopenia in Older People (EWGSOP) recently updated the European consensus on the definition and diagnosis of sarcopenia. 39, 40 Whereas the EWGSOP previously recommended using the presence of both low muscle mass and low muscle function for the diagnosis of sarcopenia, the new consensus uses low muscle strength as the primary element of sarcopenia. Several studies proposed that muscle function (defined by factors like hand grip strength or cardiopulmonary exercise testing) might be better in reflecting a patients’ physical function or nutritional status than skeletal muscle mass. 41–44 As skeletal muscle mass can be measured on routinely performed CT-scans, it is an easily available measure of the patients’ physical status. A more comprehensive picture of the patients’ physical and nutritional status might contribute to the prediction of postoperative outcomes in cancer patients. However, as mentioned previously, the patients undergoing CRS-HIPEC consist of a selected patient population. It is questionable whether a more comprehensive picture of the patients’ physical function provides significant additional value to patient selection for this specific patient population. Another limitation of this study was the limited follow-up period for surviving patients. Therefore, we presented 3-year survival data. For PMP patients, the sample size was small and median DFS and OS were not reached. Therefore, statements on the impact of low SMM on survival in these patients could not be made. Lastly, this study only investigated SMM as a predictor of postoperative survival. Sarcopenia, also defined by muscle weakness, might be a better predictor of postoperative outcomes. Previous studies reporting on the impact of sarcopenia on postoperative outcomes after general colorectal cancer surgery and CRS-HIPEC are inconsistent in the definition of sarcopenia. Future studies should investigate whether sarcopenia, defined by low SMM and muscle weakness, is a valid predictor of postoperative outcomes after CRS-HIPEC. In addition, other factors, such as weight loss and nutritional depletion, might also be relevant for the prediction of frailty and, consequently, of postoperative outcomes.

CONCLUSIONS

This study showed that low SMM was not a predictor of postoperative outcomes after CRS-HIPEC. This is probably explained by strict patient selection, based on factors like fitness for major surgery. Morbidity after CRS-HIPEC is considerable, nonetheless. This morbidity might be more acceptable in patients with long-term disease-free and overall survival. Hence, future research should focus on the identification of prognostic factors useful in preoperative patient selection.

DISCLOSURES No conflict of interests.
RACE/ETHNICITY DATA The race/ethnicity distribution was not reported, as this data was not collected in the database that was analyzed for this study. As this is a retrospective study, this data could not be obtained.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1245/s10434-022-11941-2.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Verwaal V, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43. https://doi.org/10.1200/JCO.2003.04.187.

2. Koppe M, Boermann OC, Oyen WJG, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243:212–22. https://doi.org/10.1097/01.sla.0000197702.46394.16.

3. Verwaal V, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32. https://doi.org/10.1245/s10434-008-9966-2.

4. Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–86. https://doi.org/10.1200/JCO.2009.23.9285.

5. Quénét F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256–66. https://doi.org/10.1016/s1470-2045(20)30599-4.

6. Chua T, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56. https://doi.org/10.1200/JCO.2011.39.7166.

7. Bartlett E, Meise C, Roses RE, Fraker DL, Kelz RR, Karakousis GC. Morbidity and mortality of cytoreduction with intraperitoneal chemotherapy: outcomes from the ACS NSQIP database. Ann Surg Oncol. 2014;21:1494–500. https://doi.org/10.1245/s10434-013-3223-z.

8. Fajari M, Halabi WJ, Stamos MJ, et al. Surgical outcomes of hyperthermic intraperitoneal chemotherapy. JAMA Surg. 2014;149(2):170–5. https://doi.org/10.1001/jamasurg.2013.3640.

9. Simkens G, van Oudheusden TR, Luyer MD, et al. Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2015;22:2656–62. https://doi.org/10.1245/s10434-014-4297-y.

10. Choudry M, Shuai Y, Jones HL, et al. Postoperative complications independently predict cancer-related survival in peritoneal malignancies. Ann Surg Oncol. 2018;25:3950–9. https://doi.org/10.1245/s10434-018-6823-9.

11. Martin L, Birdsell L, MacDonald N, Reiman T, Cladinini MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–47. https://doi.org/10.1200/jco.2012.45.2722.

12. Levolger S, van Vugt JLA, de Bruin RWF, Uzermans INM. Systematic review of sarcopenia in patients operated on or gastrointestinal and hepatopancreaticobiliary malignancies. Br J Surg. 2015;102:1448–58. https://doi.org/10.1002/bjs.9893.

13. Chai WV, Chia M, Cocco A, Bhamidipaty M, D’Souza B. Sarcopenia is a strong predictive factor of clinical and oncological outcomes following curative colorectal cancer resection. ANZ J Surg. 2021;91(5):E292–7. https://doi.org/10.1111/ans.16706.

14. Schaffler-Schaden D, Mittermair C, Birsak T, et al. Skeletal muscle index is an independent predictor of early recurrence in non-obese colon cancer patients. Langenbecks Arch Surg. 2020;405(4):669–77. https://doi.org/10.1007/s00423-020-01901-3.

15. Wang S, Xie H, Gong Y, et al. The value of L3 skeletal muscle index in evaluating preoperative nutritional risk and long-term prognosis in colorectal cancer patients. Sci Rep. 2020;10(1):8153. https://doi.org/10.1038/s41598-020-65091-0.

16. van Vugt JLA, Coebergh van den Braak RRJ, Lalmahomed ZS, et al. Impact of low skeletal muscle mass and density on short and long-term outcome after resection of stage I-III colorectal cancer. Eur J Surg Oncol. 2018;44(9):1354–60. https://doi.org/10.1016/j.ejso.2018.05.029.

17. van Vugt J, Braam HJ, van Oudheusden TR, et al. Skeletal muscle depletion is associated with severe postoperative complications in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2015;22:3625–31. https://doi.org/10.1245/s10434-015-4429-z.

18. Chemama S, Bayar MA, Lanoy E, et al. Sarcopenia is Associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol. 2016;23(12):3891–8. https://doi.org/10.1245/s10434-016-3560-7.

19. Banaste N, Rouset P, Mercier F, et al. Preoperative nutritional risk assessment in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal carcinomatosis. Int J Hyper. 2018;34(5):589–94. https://doi.org/10.1080/02656736.2017.1371342.

20. Galan A, Rouset P, Mercier F, et al. Overall survival of pseudomyxoma peritonei and peritoneal mesothelioma patients after cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy can be predicted by computed tomography quantified sarcopenia. Eur J Surg Oncol. 2018;44:1818–23. https://doi.org/10.1016/j.ejso.2018.07.060.

21. Kuijpers A, Mircik B, Aalbers AGJ, et al. Cytoreduction and HIPEC in The Netherlands: nationwide long-term outcome following the dutch protocol. Ann Surg Oncol. 2013;20:4224–30. https://doi.org/10.1245/s10434-013-3145-9.

22. Kuijpers A, Aalbers AGJ, Nienhuijs SW, et al. Implementation of a standardized HIPEC protocol improves outcome for peritoneal malignancy. World J Surg. 2015;39:453–60. https://doi.org/10.1007/s00268-014-2801-y.
23. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74. https://doi.org/10.1007/978-1-4613-1247-5_23.

24. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.

25. van Vugt J, Levolger S, Ghabharan A, et al. A comparative study of software programmes for cross-sectional skeletal muscle and adipose tissue measurements on abdominal computed tomography scans of rectal cancer patients. J Cachexia Sarcopenia Muscle. 2017;8:285–97. https://doi.org/10.1002/jcem.12158.

26. Simkens G, van Oudheusden TR, Luyer MD, et al. Predictors of severe morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2016;23:833–41. https://doi.org/10.1245/s10434-015-4892-6.

27. Oemrawsing A, de Boer NL, Brandt-Kerkhof ARM, Verhoef C, Peters M, Bartlett EK, Roses RE, Kelz RR, Fraker DL, Karakousis GC. Age-related morbidity and mortality with cytoreductive surgery. Ann Surg Oncol. 2015;22:898–904. https://doi.org/10.1245/s10434-015-4624-y.

28. Peters M, Bartlett EK, Roses RE, Kelz RR, Fraker DL, Karakousis GC. Age-related morbidity and mortality with cytoreductive surgery. Ann Surg Oncol. 2015;22:898–904. https://doi.org/10.1245/s10434-015-4624-y.

29. Lieffers J, Bathe OF, Fassbender K, Winget M, Baraco VE. Functional recovery from colorectal cancer resection surgery. J Surg Oncol. 2012;107:931–6. https://doi.org/10.1038/bjc.2012.350.

30. Reisinger KW, van Vugt JLA, Tegels JJW, et al. Functional complications in elderly gastric cancer patients undergoing gastrectomy. ANZ J Surg. 2018;88(7–8):723–6. https://doi.org/10.1111/ans.14325.

31. Prado C, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629–35. https://doi.org/10.1016/S1470-2245(08)70153-0.

32. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489–95. https://doi.org/10.1016/S1470-2245(10)70218-7.

33. van Kooten JP, Oemrawsingh A, de Boer NL, et al. Predictive ability of c-reactive protein in detecting short-term complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a retrospective cross-sectional study. Ann Surg Oncol. 2021;28(1):233–243. https://doi.org/10.1245/s10434-020-08619-y.

34. Kirchhoff P, Clavien PA, Hahnloser D. Complications in colorectal surgery: risk factors and preventive strategies. Patient Saf Surg. 2010;4(1):5. https://doi.org/10.1186/1754-9493-4-5.

35. Lipska M, Bissett IP, Parry BR, Merrie AEH. Anastomotic leakage after lower gastrointestinal anastomosis: men are at higher risk. ANZ J Surg. 2006;76(7):579–85. https://doi.org/10.1111/j.1445-2197.2006.03780.x.

36. Elliott JA, Doyle SL, Murphy CF, et al. Sarcopenia: prevalence, and impact on operative and oncologic outcomes in the multimodal management of locally advanced esophageal cancer. Ann Surg. 2017;266(5):822–30. https://doi.org/10.1097/SLA.000000000002398.

37. Reisinger KW, Bosmans JWAM, Uittenbogaart M, et al. Loss of skeletal muscle mass during neoadjuvant chemoradiotherapy predicts postoperative mortality in esophageal cancer surgery. Ann Surg Oncol. 2015;22(13):4445–52. https://doi.org/10.1245/s10434-015-4558-4.

38. Awad S, Tan BH, Cui H, et al. Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr. 2012;31(1):74–7. https://doi.org/10.1016/j.clnut.2011.08.008.

39. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39(4):412–23. https://doi.org/10.1093/ageing/afq034.

40. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age and Ageing. 2019;48(1):16–31. https://doi.org/10.1093/ageing/afy169.

41. Sato T, Aoyama T, Hayashi T, et al. Impact of preoperative hand grip strength on morbidity following gastric cancer surgery. Gastric Cancer. 2016;19(3):1008–15. https://doi.org/10.1007/s10120-015-0554-4.

42. Chandoo A, Chi C-H, Ji W, et al. Gait speed predicts post-operative medical complications in elderly gastric cancer patients undergoing gastrectomy. ANZ J Surg. 2018;88(7–8):723–6. https://doi.org/10.1111/ans.14325.

43. Tanaka K, Taoda A, Kashiwagi H. The associations between nutritional status, physical function and skeletal muscle mass of geriatric patients with colorectal cancer. Clin Nutr ESPEN. 2021;41:318–24. https://doi.org/10.1016/j.clnesp.2020.11.009.

44. West MA, Baker WCA, Rahman S, et al. Cardiopulmonary exercise testing has greater prognostic value than sarcopenia in oesophago-gastric cancer patients undergoing neoadjuvant therapy and surgical resection. J Surg Oncol. 2021;124(8):1306–16. https://doi.org/10.1002/jso.26652.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.